These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32627005)

  • 1. Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.
    Hu K; Xie W; Ni S; Yan S; Tian G; Qi W; Duan Y
    Oncol Rep; 2020 Aug; 44(2):650-660. PubMed ID: 32627005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 mediates methotrexate resistance in osteosarcoma cells by promoting autophagy.
    Wang L; Zhai D; Tang L; Zhang H; Wang X; Ma N; Zhang X; Cheng M; Shen R
    Acta Biochim Biophys Sin (Shanghai); 2024 Jul; 56(9):1289-1299. PubMed ID: 39086352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.
    Li Y; Zhang T; Zhang Y; Zhao X; Wang W
    Cancer Sci; 2018 Oct; 109(10):3093-3104. PubMed ID: 30099814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.
    Cheng C; Ding Q; Zhang Z; Wang S; Zhong B; Huang X; Shao Z
    J Cell Mol Med; 2020 May; 24(9):5274-5289. PubMed ID: 32207235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
    Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
    Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of beclin1 affects the chemotherapeutic sensitivity of osteosarcoma.
    Wu W; Li W; Zhou Y; Zhang C
    Int J Clin Exp Pathol; 2014; 7(10):7114-22. PubMed ID: 25400807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
    Tsai HC; Huang CY; Su HL; Tang CH
    PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
    Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
    J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.
    Zhou X; Natino D; Zhai X; Gao Z; He X
    Mol Med Rep; 2018 May; 17(5):7209-7217. PubMed ID: 29568877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
    Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
    Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
    Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
    Hu Y; Gu J; Shen H; Shao T; Li S; Wang W; Yu Z
    J Clin Lab Anal; 2020 Feb; 34(2):e23045. PubMed ID: 31642110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXM1 contributes to treatment failure in acute myeloid leukemia.
    Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
    Sun X; Wei Q; Cheng J; Bian Y; Tian C; Hu Y; Li H
    Hum Cell; 2017 Jul; 30(3):216-225. PubMed ID: 28326487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive bioinformatics analysis reveals the oncogenic role of FoxM1 and its impact on prognosis, immune microenvironment, and drug sensitivity in osteosarcoma.
    Shi S; Wang Q; Du X
    J Appl Genet; 2023 Dec; 64(4):779-796. PubMed ID: 37782449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
    Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
    Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines.
    Choi HS; Kim YK; Hwang KG; Yun PY
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
    He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
    Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-216b inhibits osteosarcoma cell proliferation, migration, and invasion by targeting Forkhead Box M1.
    Wang W; Guo Z; Yu H; Fan L
    J Cell Biochem; 2019 Apr; 120(4):5435-5443. PubMed ID: 30302807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
    Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
    J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.